Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: Results from 12 years of observation

Clinical Infectious Diseases

Volumn 57, Issue 10, 2013, Pages 1489-1496

  Laprise, Claudie ^a   De Pokomandy, Alexandra ^b,c   Baril, Jean Guy ^d   Dufresne, Serge ^d   Trottier, Helen ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d Clinique Medicale du Quartier Latin   (Canada)

Author keywords

Cohort study; HIV; Low level viremia; Viral load; Virological failure

Indexed keywords

ABACAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LOPINAVIR; RALTEGRAVIR; RITONAVIR; TENOFOVIR; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CANADA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBSERVATION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; VIREMIA; VIROLOGY; VIRUS LOAD;

COHORT STUDY; HIV; LOW-LEVEL VIREMIA; VIRAL LOAD; VIROLOGICAL FAILURE;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TREATMENT FAILURE; VIRAL LOAD; VIREMIA;

EID: 84887987692     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit529     Document Type: Article

References (15)

1. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-9.
2. Palella FJ J.r., Delaney KM, Moorman A.C., et al Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Department of Health and Human Services. Available at: http://aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf. Accessed 8 July 2013.
4. Cohen C. Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen. HIV Clin Trials 2009; 10: 116-24.
5. Greub G, Cozzi-Lepri A, Ledergerber B., et al Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002; 16: 1967-9.
6. Geretti AM, Smith C, Haberl A., et al Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther 2008; 13: 927-36.
7. Garcia-Gasco P., Maida I, Blanco F., et al Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother 2008; 61: 699-704.
8. Sungkanuparph S, Groger RK, Overton E.T., Fraser VJ, Powderly WG Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy. HIV Med 2006; 7: 437-41.
9. Pham T, Alrabaa S, Somboonwit C., Le H, Montero J. The HIV virologic outcomes of different interventions among treatment-experienced patients with 2 consecutive detectable low-level viremia. J Int Assoc Physicians AIDS Care (Chic) 2011; 10: 54-6.
10. Karlsson AC, Younger SR, Martin J.N., et al Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 2004; 18: 981-9.
11. Delaugerre C, Gallien S, Flandre P., et al Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. PloS one 2012; 7: e36673.
12. Taiwo B, Gallien S, Aga E., et al Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J Infect Dis 2011; 204: 515-20.
13. Nettles RE, Kieffer TL, Simmons R.P., et al Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy. Clin Infect Dis 2004; 39: 1030-7.
14. McConnell MJ, Mier-Mota J, Flor-Parra F, et al Improved viral suppression after treatment optimization in HIV-infected patients with persistent low-level viremia. J Acquir Immune Defic Syndr 2011; 58: 446-9.
15. Rossouw T, Lessels R, de Oliveira T. HIV & TB drug resistance & clinical management case book. South African medical research. Tygerberg, South Africa. 2013.